PL2585477T3 - Rearanżowane cząsteczki wirusa tt do zastosowania w diagnozowaniu, profilaktyce i leczeniu raka oraz chorób autoimmunologicznych - Google Patents

Rearanżowane cząsteczki wirusa tt do zastosowania w diagnozowaniu, profilaktyce i leczeniu raka oraz chorób autoimmunologicznych

Info

Publication number
PL2585477T3
PL2585477T3 PL11737889T PL11737889T PL2585477T3 PL 2585477 T3 PL2585477 T3 PL 2585477T3 PL 11737889 T PL11737889 T PL 11737889T PL 11737889 T PL11737889 T PL 11737889T PL 2585477 T3 PL2585477 T3 PL 2585477T3
Authority
PL
Poland
Prior art keywords
autoimmunity
rearranged
diagnosis
cancer
prevention
Prior art date
Application number
PL11737889T
Other languages
English (en)
Inventor
Ethel-Michele De Villiers
Harald Zur Hausen
Original Assignee
Deutsches Krebsforschungszentrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10006541.6A external-priority patent/EP2399928B1/en
Priority claimed from US12/821,634 external-priority patent/US20110318363A1/en
Application filed by Deutsches Krebsforschungszentrum filed Critical Deutsches Krebsforschungszentrum
Publication of PL2585477T3 publication Critical patent/PL2585477T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/00041Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
PL11737889T 2010-06-23 2011-06-24 Rearanżowane cząsteczki wirusa tt do zastosowania w diagnozowaniu, profilaktyce i leczeniu raka oraz chorób autoimmunologicznych PL2585477T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10006541.6A EP2399928B1 (en) 2010-06-23 2010-06-23 Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
US12/821,634 US20110318363A1 (en) 2010-06-23 2010-06-23 Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
US95230010A 2010-11-23 2010-11-23
EP10014907 2010-11-23
PCT/EP2011/003119 WO2011160848A1 (en) 2010-06-23 2011-06-24 Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
EP11737889.3A EP2585477B1 (en) 2010-06-23 2011-06-24 Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity

Publications (1)

Publication Number Publication Date
PL2585477T3 true PL2585477T3 (pl) 2018-12-31

Family

ID=45370870

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11737889T PL2585477T3 (pl) 2010-06-23 2011-06-24 Rearanżowane cząsteczki wirusa tt do zastosowania w diagnozowaniu, profilaktyce i leczeniu raka oraz chorób autoimmunologicznych

Country Status (10)

Country Link
EP (1) EP2585477B1 (pl)
JP (2) JP6235903B2 (pl)
AU (1) AU2011269260B2 (pl)
CA (1) CA2802964C (pl)
DK (1) DK2585477T3 (pl)
ES (1) ES2685605T3 (pl)
PL (1) PL2585477T3 (pl)
PT (1) PT2585477T (pl)
SI (1) SI2585477T1 (pl)
WO (1) WO2011160848A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585477B1 (en) * 2010-06-23 2018-05-30 Deutsches Krebsforschungszentrum Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
WO2015188899A1 (en) * 2014-06-12 2015-12-17 Deutsches Krebsforschungszentrum Novel ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
EP0702722B1 (en) 1993-06-07 2005-08-03 Vical Incorporated Plasmids suitable for gene therapy
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
TNSN99210A1 (fr) * 1998-11-10 2005-11-10 Diasorin S R L Identification de genotypes du virus sen
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
JP2003516136A (ja) * 1999-12-10 2003-05-13 ロシュ ダイアグノスティックス ゲーエムベーハー 肝炎ウイルスセンチネルウイルスi(svi)
JP2005232001A (ja) * 2000-06-22 2005-09-02 Astellas Pharma Inc 新規なロイコトリエンb4受容体
DE10144346A1 (de) * 2001-09-10 2003-04-03 Deutsches Krebsforsch TT-Virus-Sequenzen in menschlichen Tumorgeweben, Mittel zu deren Nachweis sowie Tumortherapie
US20050163776A1 (en) * 2002-03-20 2005-07-28 Raven Neil D.H. Treatment of tse infection
US20080003565A1 (en) * 2006-05-02 2008-01-03 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Viral nucleic acid microarray and method of use
EP1992691A1 (en) * 2007-05-16 2008-11-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts New TTV sequences for diagnosis, prevention and treatment of childhood leukaemia
NZ582271A (en) * 2007-06-26 2012-03-30 Japan Health Science Found Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
JP5309159B2 (ja) * 2008-01-09 2013-10-09 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション バキュロウイルスを利用したワクチン
EP2585477B1 (en) * 2010-06-23 2018-05-30 Deutsches Krebsforschungszentrum Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity

Also Published As

Publication number Publication date
ES2685605T3 (es) 2018-10-10
WO2011160848A1 (en) 2011-12-29
EP2585477B1 (en) 2018-05-30
JP2013538044A (ja) 2013-10-10
SI2585477T1 (sl) 2019-03-29
CA2802964A1 (en) 2011-12-29
JP6235903B2 (ja) 2017-11-22
AU2011269260A1 (en) 2013-01-17
JP2016103996A (ja) 2016-06-09
CA2802964C (en) 2021-08-31
EP2585477A1 (en) 2013-05-01
DK2585477T3 (en) 2018-09-03
PT2585477T (pt) 2018-10-12
WO2011160848A8 (en) 2012-04-19
AU2011269260B2 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
PT2532367T (pt) Agente farmacêutico para o tratamento e/ou prevenção do cancro
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
EP2532680A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2740793A4 (en) MEDICINAL PREPARATION FOR CANCER TREATMENT AND / OR PREVENTION
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532743A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
HK1217088A1 (zh) 微泡在醫學疾病和病况的診斷、預後和治療中的用途
HK1199712A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117-
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2606349A4 (en) AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
EP2875158A4 (en) USE OF MICROVESICLES IN THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES AND MEDICAL SUDDEN
GB0922085D0 (en) Cancer diagnosis and treatment
IL232434A0 (en) Medicine for medical treatment and/or improvement of sepsis
EP2470268A4 (en) PURING-ORIENTED DIAGNOSIS AND THERAPY OF WOUNDS
EP2575863A4 (en) USE OF SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2438167A4 (en) THERAPEUTIC AND DIAGNOSTIC MOLECULES
GB0901837D0 (en) Cancer diagnosis and treatment
SI2585477T1 (sl) Preurejene tt virusne molekule za uporabo v diagnozi, preprečevanje in zdravljenje raka in avtoimunosti
EP2336108A4 (en) TRIPYRROL-OCTAARGININE HYBRID COMPOUNDS AND USE THEREOF AS A MEDICAMENT FOR TREATING CANCER AND MICROBIAL DISEASES
EP2783685A4 (en) USE OF LEVO-OXIRACETAM AND OXIRACETAM IN THE MANUFACTURE OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF KOMA